EITR BIOLOGICS, INC.
Doing business as EITR BIOLOGICS INC
- SAN DIEGO, CA 92121-3109
- eitrbio.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $38.9M
- Awards on record
- 9
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 55 days
EITR BIOLOGICS, INC.’s registration expires on Jan 8, 2027. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About EITR BIOLOGICS, INC.
- Headquarters
- SAN DIEGO, CA 92121-3109
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIHX49LZLY32G5
- CAGE99JH0
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $38.9M
- Awards on record
- 9
- Top funding agencies
- Office of Assistant Secretary for Preparedness and Response · Defense Health Agency
Awards
HT942526FE010
Recompete 12–18 mo: Potential end Dec 31, 2027 (13 months away)NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY
Department of Defense · Defense Health Agency
- Obligated
- $927K
- Period of performance
- Feb 1, 2026 – Dec 31, 2027
75A50123C00060
Recompete 6–12 mo: Potential end Sep 30, 2027 (10 months away)THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE…
Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response
- Obligated
- $33.1M
- Period of performance
- Sep 22, 2023 – Sep 30, 2027
HT942626FE055
Recompete 6–12 mo: Potential end Jun 30, 2027 (7 months away)NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY
Department of Defense · Defense Health Agency
- Obligated
- $100K
- Period of performance
- Jul 1, 2026 – Jun 30, 2027
HT942626FE033
Recompete < 6 mo: Potential end Mar 31, 2027 (4 months away)NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY
Department of Defense · Defense Health Agency
- Obligated
- $270K
- Period of performance
- Apr 1, 2026 – Mar 31, 2027
HT942525F0221
Completed: Period of performance ended Jun 30, 2026NOVEL NANOTHERAPEUTICS
Department of Defense · Defense Health Agency
- Obligated
- $300K
- Period of performance
- Jul 1, 2025 – Jun 30, 2026
HT942524F0269
Completed: Period of performance ended Dec 31, 2025NOVEL NANOTHERAPEUTICS
Department of Defense · Defense Health Agency
- Obligated
- $1.9M
- Period of performance
- Sep 20, 2024 – Dec 31, 2025
HT942524P0015
Completed: Period of performance ended Dec 10, 2025SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AND PRODUCE MONOCLONAL ANTIBODIES FOR ASSESSMENT…
Department of Defense · Defense Health Agency
- Obligated
- $729.7K
- Period of performance
- Dec 6, 2023 – Dec 10, 2025
HT942524F0127
Completed: Period of performance ended Jun 30, 2025DEVELOP A NOVEL ODIN THERAPEUTIC MEDICAL COUNTERMEASURE CAPABLE OF PROTECTING AGAINST PNEUMONIC UNENCAPSULATED Y. PESTIS.
Department of Defense · Defense Health Agency
- Obligated
- $499.9K
- Period of performance
- Jul 1, 2024 – Jun 30, 2025
HT942523P0004
Completed: Period of performance ended Nov 27, 2024NOVEL CELL SORTING
Department of Defense · Defense Health Agency
- Obligated
- $1.1M
- Period of performance
- Nov 28, 2022 – Nov 27, 2024
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
HT942526FE010 under HT942523D0011 NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | Department of Defense · Defense Health Agency | 541714 · AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $927K | Feb 1, 2026 – Dec 31, 2027 | Recompete 12–18 mo: Potential end Dec 31, 2027 (13 months away)AI brief for award HT942526FE010Bid team for the recompete of award HT942526FE010 |
75A50123C00060 THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE… | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | 541714 · 3650CHEMICAL AND PHARMACEUTICAL PRODUCTS MANUFACTURING MACHINERY | $33.1M | Sep 22, 2023 – Sep 30, 2027 | Recompete 6–12 mo: Potential end Sep 30, 2027 (10 months away)AI brief for award 75A50123C00060Bid team for the recompete of award 75A50123C00060 |
HT942626FE055 under HT942523D0011 NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | Department of Defense · Defense Health Agency | 541714 · AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $100K | Jul 1, 2026 – Jun 30, 2027 | Recompete 6–12 mo: Potential end Jun 30, 2027 (7 months away)AI brief for award HT942626FE055Bid team for the recompete of award HT942626FE055 |
HT942626FE033 under HT942523D0011 NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | Department of Defense · Defense Health Agency | 541714 · AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $270K | Apr 1, 2026 – Mar 31, 2027 | Recompete < 6 mo: Potential end Mar 31, 2027 (4 months away)AI brief for award HT942626FE033Bid team for the recompete of award HT942626FE033 |
HT942525F0221 under HT942523D0011 NOVEL NANOTHERAPEUTICS | Department of Defense · Defense Health Agency | 541714 · AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $300K | Jul 1, 2025 – Jun 30, 2026 | Completed: Period of performance ended Jun 30, 2026 |
HT942524F0269 under HT942523D0011 NOVEL NANOTHERAPEUTICS | Department of Defense · Defense Health Agency | 541714 · AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $1.9M | Sep 20, 2024 – Dec 31, 2025 | Completed: Period of performance ended Dec 31, 2025 |
HT942524P0015 SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AND PRODUCE MONOCLONAL ANTIBODIES FOR ASSESSMENT… | Department of Defense · Defense Health Agency | 541380 · Q301REFERENCE LABORATORY TESTING | $729.7K | Dec 6, 2023 – Dec 10, 2025 | Completed: Period of performance ended Dec 10, 2025 |
HT942524F0127 under HT942523D0011 DEVELOP A NOVEL ODIN THERAPEUTIC MEDICAL COUNTERMEASURE CAPABLE OF PROTECTING AGAINST PNEUMONIC UNENCAPSULATED Y. PESTIS. | Department of Defense · Defense Health Agency | 541714 · AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $499.9K | Jul 1, 2024 – Jun 30, 2025 | Completed: Period of performance ended Jun 30, 2025 |
HT942523P0004 NOVEL CELL SORTING | Department of Defense · Defense Health Agency | 541380 · Q301REFERENCE LABORATORY TESTING | $1.1M | Nov 28, 2022 – Nov 27, 2024 | Completed: Period of performance ended Nov 27, 2024 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 3 awards
- Total awarded
- $1,583,346
- By phase
- SBIR Phase I: 2
- SBIR Phase II: 1
- By agency
- Department of Health and Human Services: 3
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 1 project
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2023: 2
Awards (most recent first)
Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,000,000
Sep 25, 2025 – Aug 31, 2027
- Active
- Ends Aug 2027
Solicitation PA22-176 (2022) · Topic NIAID
Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape
SBIR Phase I · Department of Health and Human Services (Centers for Disease Control and Prevention) · 2023 · $299,794
Sep 30, 2023 – Sep 29, 2024
Solicitation PA22-176 (2022) · Topic CDC
Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $283,552
Jul 1, 2023 – Jun 30, 2024
Solicitation PA22-176 (2022) · Topic NIAID
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
No active exclusion on record (checked Nov 14, 2026).
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · as of Nov 14, 2026
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 14, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with EITR BIOLOGICS, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
